Head-to-head evidence
Inbrija (CVT-301) vs WD-1603
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Inbrija (CVT-301)
Marketed by Merz Therapeutics
NCT02240030 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 351 participants and a clinical primary endpoint based on the UPDRS Part III motor score. Although the primary score numerically favored high-dose CVT-301 over placebo, the registry does not state whether that primary comparison was statistically significant, so the result remains unclear.
WD-1603
Developed by Hong Kong WD Pharmaceutical Co., Limited
NCT05036473 · Phase 2 · completed
This randomized, double-blind, placebo-controlled Phase 2 trial in early Parkinson's disease enrolled only 40 patients across three dose groups and placebo. All three doses of WD-1603 produced a statistically significant improvement in combined motor and daily-living function scores versus placebo at 27 days, with the largest effect at the highest dose (p=0.0003), but the very small sample size means these results need confirmation in a larger trial.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Inbrija (CVT-301)'s landscape · WD-1603's landscape